Cargando…

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin

The extent of mixed hepatitis C virus (HCV) genotype in different compartments (plasma and peripheral blood mononuclear cell, PBMC) and possible association with treatment efficacy in HIV/HCV coinfected patients remains to be unknown. The objective of this study was to elucidate the frequency of mix...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagaglio, Sabrina, Uberti-Foppa, Caterina, Di Serio, Clelia, Trentini, Filippo, Andolina, Andrea, Hasson, Hamid, Messina, Emanuela, Merli, Marco, Porrino, Lucy, Lazzarin, Adriano, Morsica, Giulia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2015
Materias:	4850
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985415/ https://www.ncbi.nlm.nih.gov/pubmed/26512601 http://dx.doi.org/10.1097/MD.0000000000001876

Ejemplares similares

Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype
por: Morsica, Giulia, et al.
Publicado: (2021)

Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates
por: Bagaglio, Sabrina, et al.
Publicado: (2018)

Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions
por: Bagaglio, Sabrina, et al.
Publicado: (2019)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome
por: Bagaglio, Sabrina, et al.
Publicado: (2020)

Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment
por: Bagaglio, Sabrina, et al.
Publicado: (2016)

Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study
por: Desai, Seema N., et al.
Publicado: (2016)

Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients
por: Sagnelli, Caterina, et al.
Publicado: (2017)

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study
por: Morsica, Giulia, et al.
Publicado: (2017)

Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC)
por: Gupta, Rahul, et al.
Publicado: (2012)

Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study
por: Focà, Emanuele, et al.
Publicado: (2016)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy
por: Sagnelli, Caterina, et al.
Publicado: (2020)

Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection
por: Alejos, Belén, et al.
Publicado: (2016)

Modelling the impact of protein-kinase R allelic variant on HIV biomarkers trajectories by means of latent class mixed models
por: Brombin, Chiara, et al.
Publicado: (2022)

Long-term follow-up of elite controllers: Higher risk of complications with HCV coinfection, no association with HIV disease progression
por: Stafford, Kristen A., et al.
Publicado: (2017)

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
por: Gianotti, Nicola, et al.
Publicado: (2016)

MELD Score Kinetics in Decompensated HIV+/HCV+ Patients: A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study)
por: Gelu-Simeon, Moana, et al.
Publicado: (2015)

Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
por: Banga, Jaspreet, et al.
Publicado: (2020)

Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study
por: Sanarico, Nunzia, et al.
Publicado: (2016)

Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2019)

European vs. Egyptian HCV-4 Patients with Elevated Baseline HCV RNA, Treated with PEG-IFN-α2a and Ribavirin: The Role of Rapid and Early Virologic Response
por: Dimitroulopoulos, Dimitrios, et al.
Publicado: (2010)

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols
por: Caputo, Valeria, et al.
Publicado: (2020)

Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients
por: Morsica, Giulia, et al.
Publicado: (2022)

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population
por: Jin, Young-Joo, et al.
Publicado: (2013)

Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report
por: Bagaglio, Sabrina, et al.
Publicado: (2009)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
por: Zhang, Yu, et al.
Publicado: (2016)

IFN-Alpha Receptor-1 Upregulation in PBMC from HCV Naïve Patients Carrying CC Genotype. Possible Role of IFN-Lambda
por: Lalle, Eleonora, et al.
Publicado: (2014)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
por: Ferretti, Francesca, et al.
Publicado: (2016)

Soluble egg antigen of Schistosoma Haematobium induces HCV replication in PBMC from patients with chronic HCV infection
por: El-Awady, Mostafa K, et al.
Publicado: (2006)

Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
por: Jia, Zhifang, et al.
Publicado: (2012)

Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report
por: d’Ettorre, Gabriella, et al.
Publicado: (2020)

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4
por: Rizk, Hanan H., et al.
Publicado: (2016)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
por: Li, Yanhua, et al.
Publicado: (2017)

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
por: Flynn, Jacqueline K, et al.
Publicado: (2014)

HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial
por: Colombatto, P, et al.
Publicado: (2014)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lduns4hkv1c7uj26e3sb2p7964